Groundbreaking for Major Tulsa Expansion of OU Health Stephenson Cancer Center
Search
Services
Services
When to Come
Locations
Menu
Give
Volunteer
Contact
Menu
Return to OU Health
Insurance & Billing
Patient Portal
Education
Health Professionals
Ways to Give
Return to OU Health
Ways To Give
Ways To Give
Ways To Give
Ways To Give
Ways To Give
To Our Family of Philanthropies
To Our Family of Philanthropies
Health Services
Find a Doctor
Find a Location
Research
Children's Patients & Families
About Oklahoma Children's
Child Life & Therapeutic Programs
Tips for Parents
Family Advisory Council
Teen Advisory Council
Family Resource Center
No Hit Zone
Send a Greeting
Patient Portals
Hospital Charges, Prices & Transparency
Request Medical Records
Insurance & Billing
Daisy Award Nomination
PHIL Award Nomination
Notice of Privacy Practices
Patient Rights & Responsibilities
OU Health Patients & Families
Careers
Fundraise
Make a Gift
Make a Gift
405-271-4700
Clinical Trials
Search Clinical Trials
Search Trials
Disease Site
Select
Anus
Bones and Joints
Brain and Nervous System
Breast
Cervix
Colon
Corpus Uteri
Esophagus
Eye and Orbit
Hodgkin Lymphoma
Ill-Defined Sites
Kaposi's Sarcoma
Kidney
Larynx
Leukemia, other
Lip, Oral Cavity and Pharynx
Liver
Lung
Lymphoid Leukemia
Melanoma, Skin
Multiple Myeloma
Multiple Sites
Mycosis Fungoides
Myeloid and Monocytic Leukemia
Non-Hodgkin Lymphoma
Other
Other Digestive Organ
Other Endocrine System
Other Female Genital
Other Hematopoietic
Other Male Genital
Other Respiratory and Intrathoracic Organs
Other Skin
Other Urinary
Ovary
Pancreas
Prostate
Rectum
Small Intestine
Soft Tissue
Stomach
Thyroid
Unknown Sites
Urinary Bladder
Clear Filters
All Clinical Trials
A Phase II Study Evaluating the effect of GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) on Second Look Laparoscopy (SLL) when Administered in Combination with Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Subjects Newly Diagnosed with Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Protocol Number: 201-21-202
Status: Open
View Details
Pre-Screening for Sensitivity to Investigational Anti-Cancer Drugs in Patients with Advanced Ovarian Cancer
Protocol Number: 2X-1000
Status: Open
View Details
Phase 2, Randomized, Prospective, Open Label, Parallel-Arm, Dose Optimization Study to Investigate the Safety, Tolerability, PK/PD, and Anti-Tumor Effect of 2X- 121 in Patients with Recurrent, Advanced Ovarian Cancer
Protocol Number: 2X-1002
Status: Open
View Details
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Protocol Number: 6637-01
Status: Open
View Details
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
Protocol Number: A012103
Status: Open
View Details
LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-risk Early-Stage Breast Cancer
Protocol Number: A012301
Status: Open
View Details
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Protocol Number: A021806
Status: Open
View Details
Randomized Phase III Trial of MFOLFIRINOX +/- NIVOLUMAB VS. FOLFOX +/- NIVOLUMAB for First - Line Treatment of Metastatic HER2-NEGATIVE Gastroesophageal Adenocarcinoma
Protocol Number: A022102
Status: Open
View Details
Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)
Protocol Number: A022106
Status: Open
View Details
A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients With DNA Muscle-Invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious Damage Response (DDR) Gene Alterations
Protocol Number: A031701
Status: Open
View Details
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
Protocol Number: A031702
Status: Open
View Details
A Phase II Randomized Trial of Radium-223 dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RADICAL)
Protocol Number: A031801
Status: Open
View Details
PREcision DIagnostics in Prostate Cancer Treatment (PREDICT)
Protocol Number: A032102
Status: Open
View Details
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Protocol Number: A032103
Status: Open
View Details
Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma -STRIKE
Protocol Number: A032201
Status: Open
View Details
